Sedana Medical Treats First U.S. Patient in FDA-Approved Early Access Sedation Program

An update from Sedana Medical AB ( (SE:SEDANA) ) is now available.

Sedana Medical has treated the first U.S. patient under its FDA‑approved Early Access Program, giving critically ill “difficult‑to‑sedate” intensive care patients access to its investigational inhaled isoflurane‑based sedation therapy ahead of formal market authorization. The milestone, achieved at Vanderbilt University Medical Center, underscores both the unmet clinical need for safer and more effective ICU sedation options and Sedana’s progress toward a planned mid‑2026 New Drug Application filing, potentially strengthening its positioning in the critical care sedation market.

The Early Access Program allows use of Sedana’s therapy in high‑risk patients who cannot be adequately managed with existing intravenous sedatives, with clinical indicators including repeated agitation, escalating sedative or opioid needs, or physician concern over continued IV use. In line with typical expanded access practices, Sedana will supply the investigational products free of charge to participating U.S. hospitals, which may help drive real‑world experience, clinician familiarity, and future adoption if the product ultimately secures FDA approval.

The most recent analyst rating on (SE:SEDANA) stock is a Hold with a SEK8.00 price target. To see the full list of analyst forecasts on Sedana Medical AB stock, see the SE:SEDANA Stock Forecast page.

More about Sedana Medical AB

Sedana Medical AB is a Stockholm‑headquartered medtech and pharmaceutical company specializing in inhaled sedation for mechanically ventilated intensive care patients. Its core offering combines the Sedaconda ACD medical device with the Sedaconda (isoflurane) pharmaceutical, and the company sells directly in key European markets while using distributors across the rest of Europe, Asia, Australia, Canada, and Latin America.

Average Trading Volume: 192,298

Technical Sentiment Signal: Strong Sell

Current Market Cap: SEK926.8M

Learn more about SEDANA stock on TipRanks’ Stock Analysis page.